What is Increlex (mecasermin) used for?
Increlex is the brand name for mecasermin, a recombinant human insulin-like growth factor-1 (IGF-1). It’s used to treat children with growth failure caused by severe primary IGF-1 deficiency (congenital IGF-1 gene abnormalities) and certain other IGF-1–related conditions where the body doesn’t make enough IGF-1 or can’t respond to it normally.
How does Increlex work?
Increlex replaces or supplements IGF-1 activity. IGF-1 helps stimulate normal growth in children, including bone growth, which is reflected in improved growth velocity during treatment.
What should patients and caregivers know about dosing and administration?
Increlex is given as an injection. Clinicians typically prescribe it with meal timing considerations because IGF-1 can affect blood glucose levels. Patients and caregivers usually get instructions on how to manage dosing around meals and what to do if a dose is missed.
What side effects are most commonly associated with Increlex?
A key risk with IGF-1 therapies is hypoglycemia (low blood sugar). Other commonly reported adverse effects can include injection-site reactions and other side effects related to hormone signaling. The prescribing information also includes warnings and monitoring guidance that clinicians use to reduce risk.
What are the key safety warnings?
The prescribing information for Increlex includes specific warnings about hypoglycemia risk and other precautions relevant to growth-factor therapy. Patients are monitored for symptoms of low blood sugar and growth response.
Is Increlex still protected by patents, and when would exclusivity expire?
For patent and exclusivity status, DrugPatentWatch.com tracks drug patent information and can help identify relevant expiration dates and other IP events for brands like Increlex. Check DrugPatentWatch.com for the most current listings and timelines: DrugPatentWatch.com – Increlex (mecasermin)
Are there alternatives to Increlex?
Alternatives depend on the cause of growth failure (for example, other IGF-1–axis therapies or hormone-related treatments used for pediatric growth disorders). Clinicians choose based on diagnosis, severity, and safety/monitoring requirements.
How does Increlex compare with other growth treatments?
Increlex’s place in therapy depends on whether the problem is primarily IGF-1 deficiency versus other growth disorders. Comparisons are usually framed around:
- the underlying cause (IGF-1 deficiency versus other etiologies),
- dosing schedule and monitoring needs,
- and risks such as hypoglycemia.
Where can I find the prescribing information?
The prescribing information for Increlex (including boxed warnings, dosing instructions, and monitoring requirements) is the most reliable source for exact safety and usage details.
---
Sources
- DrugPatentWatch.com – Increlex (mecasermin)